FDA Issues Warning Letters to 30 Telehealth Companies Over GLP-1 Marketing Claims

The Food and Drug Administration issued warning letters to 30 telehealth companies for making false or misleading claims about compounded GLP-1 medications on their websites, the agency announced today. The action represents the FDA's most significant enforcement sweep yet targeting the marketing practices of companies selling alternatives to brand-name drugs like Ozempic and Wegovy.

The warning letters cite violations including unsubstantiated efficacy claims, failure to include required risk information, and improper marketing of unapproved drug products. Companies targeted in the enforcement action have 15 business days to respond with corrective measures or face potential legal action.

Compounded GLP-1 medications have proliferated as telehealth companies seek to capitalize on shortages and high costs of FDA-approved semaglutide and tirzepatide products. Unlike branded medications, compounded versions are not required to undergo the same rigorous clinical testing for safety and efficacy, though they can be legally prescribed when prepared by licensed pharmacies for individual patients.

Marketing Claims Under Fire

The FDA's enforcement action focuses on promotional language that overstates benefits or minimizes risks. Common violations identified include claims about guaranteed weight loss results, comparisons suggesting compounded versions are equivalent to FDA-approved drugs, and failure to adequately warn patients about potential side effects.

Some companies also violated regulations by marketing compounded GLP-1s as wholesale alternatives to prescription medications, rather than patient-specific preparations as required under compounding pharmacy rules.

The agency has not publicly named the 30 companies that received warning letters, though it typically publishes such correspondence on its website within weeks of issuance.

Patient Safety Implications

For patients currently using compounded GLP-1 medications obtained through telehealth platforms, the FDA's action does not immediately affect access to their prescriptions. However, companies that fail to address marketing violations could face injunctions or other enforcement actions that might disrupt services.

Patients should verify that their telehealth provider works with licensed compounding pharmacies and provides clear information about the differences between compounded and FDA-approved medications. The FDA recommends discussing treatment options with healthcare providers who can assess individual medical histories and monitoring needs.

The enforcement action comes as the agency faces pressure to address safety concerns about compounded GLP-1s while maintaining access during ongoing shortages of brand-name products. Recent data from poison control centers show increased reports of adverse events linked to compounded semaglutide, though causality remains under investigation.

Patients considering GLP-1 treatment should weigh the regulatory oversight and clinical evidence supporting FDA-approved options against the potential cost savings and availability of compounded alternatives. Those already using compounded medications should monitor for unusual side effects and maintain regular contact with prescribing physicians.